Abstract | BACKGROUND: METHODS: After thorough searching of online databases, total 27 articles were included into qualitative systematic review and 5 of them were used to conduct qualitative meta-analysis. RESULTS: It was found that most of HITHOC was used in combination of cytoreductive surgery (CRS) including pleurectomy/decortication or after surgical resection of primary tumors, which mainly were lung cancer, thymoma or thymic carcinoma, breast cancer, and ovarian cancer. Patients who received HITHOC had significantly longer median survival length compared to the patients without HITHOC (Hedges g = 0.763, P < 0.001). In addition, HITHOC therapy was favored (Hedges g = 0.848, P < 0.001) in terms of median survival length, tumor-free survival rate, with tumor survival rate or Karnofsky performance status (KPS) scale. CONCLUSION:
|
Authors | Hua Zhou, Wei Wu, Xiaoping Tang, Jianying Zhou, Yihong Shen |
Journal | Medicine
(Medicine (Baltimore))
Vol. 96
Issue 1
Pg. e5532
(Jan 2017)
ISSN: 1536-5964 [Electronic] United States |
PMID | 28072694
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
|
Topics |
- Antineoplastic Agents
(administration & dosage)
- Chemotherapy, Cancer, Regional Perfusion
(methods)
- Combined Modality Therapy
(methods)
- Cytoreduction Surgical Procedures
(methods)
- Humans
- Hyperthermia, Induced
(methods)
- Neoplasm Staging
- Palliative Care
(methods)
- Pleural Effusion, Malignant
(pathology, therapy)
- Survival Analysis
- Thoracic Cavity
(pathology)
- Thoracic Surgical Procedures
(methods)
|